As Expected, Nasdaq Says Tripos is 'Shell,' Threatens Delisting | GenomeWeb
NEW YORK (GenomeWeb News) — Nasdaq has notified Tripos that it can be delisted from the Nasdaq Global Market and from the Nasdaq Stock Market because it has become a “public shell” after selling its Discovery Research and Discovery Informatics branches.
 
Tripos, which said it has been anticipating the notice, said it will meet with the exchange June 28 to review the matter.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.